In fact, inhibitors of tumor necrosis factor α, a downstream effector cytokine of MAPK signaling pathway in APC with TLR4 stimulation, remarkably ameliorated clinical symptoms in patients with BD [126, 127]. Here, TLR4 is linked to Behcet disease.